| Name | Title | Contact Details |
|---|
Equality Health, LLC is a Phoenix-based whole-health delivery system focused on transforming value-based care delivery with population-specific programs that improve access, quality, and member trust. Through an integrated technology and services platform, culturally competent provider network and personalized care model, Equality Health helps managed care plans and health systems improve outcomes for diverse populations while simultaneously making the transition to risk-based accountability.
Eniva Corporation is a Anoka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Priority Life Care, a family-owned company, was built on the thought that every senior deserves quality care regardless of their economic background. With over a decade of experience, the family has been a pioneer in the industry giving a win-win solution for both seniors and coworkers (the #PLCfamily). Our focus on senior living includes independent living, assisted living, and memory care. The key to our approach is in our purpose of supporting independence. In addition to care, our residents are able to continue living out their lives with healthy choices tailored to their individual needs.
HealtheTech, Inc. is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.